Navigation Links
Source of molecular triggers in cutaneous T cell lymphoma identified

In a study published in the journal Blood, Yale scientists identify the molecular triggers that stimulate Cutaneous T Cell Lymphoma (CTCL) cells to clonally expand into large populations of malignant lymphocytes.

CTCL is the most common adult malignancy of T lymphocytes, the white blood cells of the immune system. Finding CTCL triggering factors has been a major goal of Richard L. Edelson, M.D., Director of the Yale Cancer Center, and professor and chair of dermatology at Yale, since he and his colleagues at the National Cancer Institute first identified CTCL as a separate category of lymphoma thirty years ago.

The Yale research group reported that, like all T cells, the cancerous CTCL cells require antigenic stimuli delivered by specialized dendritic cells of the epidermis, referred to as Langerhans cells (LC), in order to replicate.

To determine the nature of the activating antigen, Carole Berger, a research scientist in dermatology set up a physiologic laboratory system mimicking the tight relationship in vivo between CTCL cells and LC. The research team considered three broad categories of antigen as the source of the signal: the protein products of tumor viruses, of mutated genes, and of normal but usually inactive genes.

The study reports that CTCL develops from a small subset of lymphocytes that are pre-programmed to respond to self-antigens exposed during normal cell death. As cells undergo the process of apoptosis, cryptic -- or masked -- antigens, are uncovered. Those newly available antigens are presented by LC directly to CTCL receptors, stimulating the malignant cells rapidly divide.

"This finding has broad implications for the understanding, diagnosis, and treatment of CTCL, as well as potentially contributing to the investigation of other types of lymphomas," said Edelson. "It may now be possible to identify specific antigens and target the malignant cells with selective poisons delivered through the vehicle of L C."

The study also showed that CTCL cells, after stimulation by LC, become functioning regulatory T (Treg) cells that suppress the immune responses of normal T cells to microbial agents. This may explain the susceptibility of patients with extensive CTCL to opportunistic infections.

"Through understanding T cell and dendritic cell interactions, we may gain the ability to manage a spectrum of maladies ranging from cancer to disorders of immune regulation," said Edelson. "Inhibiting Treg-cell generation may be useful for cancer immunotherapy and promoting Treg development may be useful to induce tolerance in autoimmune disease and transplantation,"


'"/>

Source:Yale University


Related biology news :

1. Finding Cures For Tropical Diseases: Is Open Source An Answer?
2. Placenta Is A Rich Source Of Blood Stem Cells
3. Open Source Biotechnology alliance for international agriculture
4. Source of crucial immune cell in the skin discovered
5. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
6. Plants, animals share molecular growth mechanisms
7. NYU researchers simulate molecular biological clock
8. Scientists reveal molecular secrets of the malaria parasite
9. Scientists identify molecular events that drive cell senescence
10. Researchers discover molecular mechanism that desensitizes us to cold
11. Findings have implications for tracking disease, drugs at the molecular level
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: